Research programme: anti-CD62 monoclonal antibodies - LigoCyte

Drug Profile

Research programme: anti-CD62 monoclonal antibodies - LigoCyte

Alternative Names: Anti-E/L-selectin monoclonal antibody - LigoCyte; EL 246; Eleuquin

Latest Information Update: 13 Oct 2013

Price : $50

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer LigoCyte Pharmaceuticals; Takeda
  • Class Monoclonal antibodies
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic obstructive pulmonary disease

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease
  • Discontinued Acute lung injury; Inflammation; Reperfusion injury; Rheumatoid arthritis

Most Recent Events

  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
  • 18 Nov 2010 Research programme: anti-CD62 monoclonal antibodies - LigoCyte is available for licensing as of 18 Nov 2010.
  • 07 Feb 2007 Preclinical trials in Chronic obstructive pulmonary disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top